Drug Profile
L 748731
Latest Information Update: 23 Mar 2000
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Banyu; Merck & Co
- Class Antirheumatics; Nonsteroidal anti-inflammatories
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatic disorders; Rheumatoid arthritis
Most Recent Events
- 23 Mar 2000 No-Development-Reported for Rheumatic disorders in Japan (Unknown route)
- 23 Mar 2000 No-Development-Reported for Rheumatoid arthritis in USA (Unknown route)
- 17 Jun 1996 Phase-I clinical trials for Rheumatic disorders in Japan (Unknown route)